消化性溃疡 中国就医指南

Peptic ulcer disease (PUD) refers to a break or sore in the mucosal lining of the stomach (gastric ulcer) or the first part of the small intestine (duodenal ulcer). These lesions result from an imbalance between aggressive factors—primarily gastric acid and pepsin—and the protective mechanisms of the mucosa, including mucus secretion, bicarbonate production, epithelial cell renewal, and adequate mucosal blood flow. The two dominant etiologies are infection with Helicobacter pylori (H. pylori), present in over 90% of duodenal ulcers and 70–80% of gastric ulcers, and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase-1 (COX-1) and impair prostaglandin-mediated mucosal defense. Less common causes include Zollinger-Ellison syndrome, Crohn’s disease, malignancy (e.g., gastric adenocarcinoma or lymphoma), severe physiological stress (e.g., ICU patients with critical illness), and smoking—though smoking does not initiate ulcers, it impairs healing and increases recurrence risk. Epidemiologically, PUD affects approximately 5–10% of the global population at some point in life, with higher prevalence in older adults and in regions with limited access to H. pylori eradication therapy. In China, age-standardized incidence is estimated at 120–180 cases per 100,000 person-years, with duodenal ulcers more common than gastric ulcers (ratio ~3:1). Key modifiable risk factors include NSAID use (especially without gastroprotection), smoking, heavy alcohol consumption, untreated H. pylori infection, and prolonged psychological stress—though stress alone is not causative. Uncomplicated ulcers may cause intermittent epigastric pain (often burning or gnawing), bloating, early satiety, nausea, or hematemesis/melena if bleeding occurs. Complications—including gastrointestinal hemorrhage, perforation, gastric outlet obstruction, and malignant transformation (rare in duodenal ulcers but relevant in gastric ulcers)—significantly increase morbidity and mortality. Quality of life impact is substantial: chronic pain disrupts sleep, work productivity, dietary habits, and mental health; recurrent symptoms lead to anxiety about complications and frequent healthcare utilization; and long-term proton pump inhibitor (PPI) dependence may raise concerns about nutrient absorption (e.g., magnesium, vitamin B12) and bone health. Early diagnosis via upper endoscopy—gold standard for visualization, biopsy, and H. pylori testing—is essential to differentiate benign ulcers from malignancy and guide targeted therapy. With appropriate management, most ulcers heal within weeks and recurrence rates drop dramatically after successful H. pylori eradication.

# 消化性溃疡治疗方案与费用明细（消化内科）

一、非手术保守治疗（一线首选）

• •适用人群：初发、无并发症、Hp阳性或阴性轻中度溃疡患者
• •药物方案：

- 维持抑酸（PPI单药）：300–900元/月（奥美拉唑至艾司奥美拉唑梯度）

• •必需检查费：胃镜（含活检）650–1,200元；Hp检测（C13/C14呼气试验）200–350元；血常规+肝肾功180–320元

二、内镜下介入治疗（微创）

• •适用人群：活动性出血、浅表穿孔、内镜下可见血管裸露者
• •方案：内镜下注射+钛夹+APC止血/溃疡覆盖术
• •全套费用：4,500–9,800元（含术前检查、麻醉、耗材、术后监护3天）

三、外科手术（急诊/根治性）

• •适用人群：顽固穿孔、大出血经内镜失败、瘢痕性幽门梗阻
• •术式：腹腔镜穿孔修补术或胃大部切除术
• •全套费用：28,000–52,000元（含术前强化检查、手术费、ICU监护、病理及7天住院）

四、特殊复杂方案

• •耐药Hp感染（需培养+药敏）：加收检测费1,500元，个体化方案总费用3,500–6,000元
• •复合并发症（出血+穿孔）：多学科联合管理，总费用≥45,000元

方案快速选择指南

• •预算≤3,000元/年：标准四联+规范随访（90%患者适用）
• •突发呕血/黑便：立即内镜介入（优先选三甲消化内镜中心）
• •反复发作≥3次/年或药物无效：启动Hp耐药检测+外科评估